TrueMark Investments LLC Raises Stock Position in Natera, Inc. $NTRA

TrueMark Investments LLC raised its stake in Natera, Inc. (NASDAQ:NTRA) by 19.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,193 shares of the medical research company’s stock after buying an additional 1,157 shares during the period. TrueMark Investments LLC’s holdings in Natera were worth $1,215,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of Jackson Hole Trust purchased a new position in Natera in the first quarter valued at about $29,000. ORG Partners LLC purchased a new position in shares of Natera during the 1st quarter worth approximately $32,000. TCTC Holdings LLC increased its stake in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after purchasing an additional 106 shares in the last quarter. Finally, Hilltop National Bank purchased a new position in shares of Natera during the 2nd quarter worth approximately $33,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NTRA. Stephens reissued an “overweight” rating and set a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Wells Fargo & Company began coverage on shares of Natera in a research note on Monday, September 22nd. They set an “equal weight” rating and a $175.00 price objective for the company. Canaccord Genuity Group reissued a “buy” rating and set a $200.00 price objective on shares of Natera in a research note on Tuesday, October 14th. Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 price objective for the company in a research note on Monday, July 28th. Finally, Cowen reissued a “buy” rating on shares of Natera in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $196.81.

Insider Activity at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This trade represents a 31.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Friday, August 1st. The shares were sold at an average price of $132.89, for a total transaction of $398,670.00. Following the completion of the transaction, the insider owned 123,059 shares in the company, valued at approximately $16,353,310.51. This trade represents a 2.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,464 shares of company stock worth $10,963,125 in the last 90 days. Company insiders own 5.63% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $181.69 on Friday. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $187.34. The firm’s 50 day moving average price is $168.19 and its 200 day moving average price is $158.46. The firm has a market cap of $24.94 billion, a P/E ratio of -95.13 and a beta of 1.74.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same quarter last year, the business posted ($0.30) EPS. The firm’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.